Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

GSK4527226 · AL 101

Other · developed by Alector

Phase 2 Most advanced trial

ALEC Developer

1 Registered trials

What is GSK4527226?

GSK4527226 (also known as AL 101) is a drug studied in Alzheimer's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AL 101
Drug type: Other
Therapy area: Neurology
Developer: Alector Inc. (ALEC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: YRU8TD2FZD

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07105709	Phase 2	Alzheimer's Disease	Recruiting	ALEC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer's Disease

More from Alector

AL002 Phase 2 AL003 Phase 1 Osugacestat Phase 1

Sources

ClinicalTrials.gov NCT07105709

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALEC page.

Follow ALEC, the company behind GSK4527226

See ALEC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALEC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z